Extensive research has consistently demonstrated that immune checkpoint inhibitors [29] and BRAF/MEK inhibitors [100] significantly improve survival rates in patients with advanced melanoma, including stages III and IV (see above and Table 1). Here, MAP2K7 is linked to melanoma.